403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Sandhoff Disease Treatment Market Size Projects USD 456.42 Million By 2034
| Metric | Details | |
| Market Size in 2025 | USD 274.95 Million | |
| Projected Market Size in 2034 | USD 456.42 Million | |
| CAGR (2025 - 2034) | 5.75 | % |
| Leading Region | North America Share by 48% | |
| Market Segmentation | By Therapy Type, By Disease Form, By Drug Type, By End User, By Region | |
| Top Key Players | Denali Therapeutics, Sio Gene Therapies (formerly Axovant Gene Therapies), Taysha Gene Therapies, Passage Bio, Orchard Therapeutics, REGENXBIO Inc., uniQure N.V., Sanofi S.A., Johnson & Johnson (Janssen R&D), Takeda Pharmaceutical Company, Novartis AG, Amicus Therapeutics, Biomarin Pharmaceutical Inc., Pfizer Inc. (gene therapy platforms), Genzyme (Sanofi division), Bluebird Bio, Cure Rare Disease (CRD), M6P Therapeutics, IntraBio Inc., National Institutes of Health (NIH) |
Booming Clinical Trials: Major Potential
Clinical trials are conducted to assess the safety and efficacy of novel treatment regimens for Sandhoff disease. The increasing clinical trials is a result of growing research and development activities. As of October 2025, a total of 25 clinical trials were registered on the website related to Sandhoff disease. Current clinical trials focus on evaluating gene therapy candidates properties of novel drugsLack of Effective Treatments: Major Limitation
Currently, there are no specific cures for Sandhoff disease. The drugs prescribed by healthcare professionals can only provide symptomatic relief. Effective treatment regimens are not available that can enter the brain. This leads to the buildup of fatty substances in the brain, causing neurological damage.
The Sandhoff Disease Treatment Market: Regional Analysis
North America held a major revenue share by 48% of the market in 2024. The presence of key players, the availability of state-of-the-art research and development facilities, and favorable government support are the major growth factors of the market in North America. Government organizations support the development of personalized medicines for rare disorders through initiatives and funding. The presence of an advanced clinical trial infrastructure encourages researchers to develop innovative therapeutics.
The U.S. states conduct newborn screening programs to screen newborns for many serious disorders, including spinal muscular atrophy, cystic fibrosis, lysosomal storage diseases, and immunodeficiencies. The estimated prevalence of Sandhoff disease in the U.S. is between 1 in 500,000 and 1 in 1,500,000.
Canada's Drug Agency recently published a new guidance to support newborn screening programs in Canada to support the National Strategy for Drugs for Rare Diseases. In November 2024, McMaster researchers identified the role of 4-phenylbutyric acid (4-PBA), an FDA-approved product for another condition, for the treatment of Sandhoff and Tay-Sachs diseases.
Download the single region market report @Asia-Pacific is expected to witness the fastest growth in the Sandhoff disease treatment market during the predicted timeframe.
The increasing incidence of rare disorders and the growing demand for personalized medicines augment the market. The burgeoning biopharmaceutical sector
The Indian government's National Fund for Rare Diseases (NFRD) has a budget of Rs 974 crore for 2024-25 and 2025-26 for a centralized information portal and enhanced public awareness. The Ministry of Health and Family Welfare (MoHFW) announced a similar or higher amount for 2026-27 and 2027-28.
The Sandhoff Disease Treatment Market: Segmentation Analysis
By Therapy Type
The supportive & symptomatic treatment segment held a dominant presence in the market in 2024, due to a lack of effective treatment regimens. Supportive care in acute infantile Sandhoff disease focuses on providing adequate nutrition and hydration. It is comparatively cost-effective, enhancing patient convenience.
The gene therapy segment is expected to grow at the fastest CAGR in the market during the forecast period. Gene therapy offers unprecedented advantages to treat any kind of rare disorder, including Sandhoff disease. Out of the total 25 clinical trials for Sandhoff disease, 3 are based on evaluating gene therapy for its treatment.
Become a valued research partner with us -By Disease Form Type
The infantile Sandhoff disease segment held the largest revenue share of the Sandhoff disease treatment market in 2024, due to hereditary reasons, i.e., both parents carry the gene causing Sandhoff disease that is passed onto the child. Infantile Sandhoff disease is the most common type, affecting children less than 6 months of age. It results in slow developmental progress and severe neurologic impairment.
The adult Sandhoff disease segment is expected to grow with the highest CAGR in the market during the studied years. Late-onset Sandhoff disease is caused in older teens and young adults, leading to certain neurologic and psychiatric findings. Psychiatric medications, such as haloperidol and chlorpromazine, are estimated to worsen the condition in adults. The growing awareness of disease diagnosis boosts the segment's growth.
By Drug Type
The anticonvulsants & muscle relaxants segment contributed the biggest revenue share of the Sandhoff disease treatment market in 2024, due to the need to manage seizures and spasticity. As Sandhoff disease affects nerve functioning, anticonvulsants and muscle relaxants prove to be beneficial in providing symptomatic relief to patients, improving the quality of life of individuals.
The experimental gene therapies segment is expected to expand rapidly in the market in the coming years. Gene therapy is developed to introduce a functional copy of the HEXB gene to restore enzyme activity. Gene therapies for Sandhoff disease are currently under investigation, and more research is needed for human trials.
By Route of Administration
The oral segment accounted for the highest revenue share of the Sandhoff disease treatment market in 2024, due to enhanced patient convenience and cost-effective treatments. The oral route eliminates the need for skilled professionals to administer therapeutics. Anticonvulsants and antispasmodics are usually administered through the oral route. They result in fewer side effects compared to the intravenous route.
The intrathecal/intravenous segment is expected to witness the fastest growth in the market over the forecast period. The intravenous route is essential to deliver innovative gene therapies as they are unstable through the oral route. It results in higher bioavailability and prevents the first-pass metabolism. Drugs delivered through this route lead to a faster onset of action.
Get the latest insights on life science industry segmentation with our Annual Membership:By End-User
The hospitals & specialized clinics segment led the Sandhoff disease treatment market in 2024, due to the presence of favorable infrastructure and suitable capital investments. Hospitals and specialized clinics possess skilled professionals to provide personalized treatment and care to patients. They also have specialized equipment for the diagnosis, treatment, and rehabilitation of Sandhoff disease. They conduct clinical trials, benefiting patients by accessing novel therapeutics before market approval.
The academic medical centers segment is expected to show the fastest growth over the forecast period. Academic medical centers conduct research activities and clinical trials for patients with Sandhoff disease. They provide affordable treatment and have trained professionals.
Top Companies & Their Contributions in the Market
| Companies | Contributions |
| Denali Therapeutics | The U.S.-based company is dedicated to defeating neurodegenerative and lysosomal storage diseases through rigorous therapeutic discovery and development. |
| Sio Gene Therapies | The company is testing its intravenous gene therapy with a bicistronic AAV vector in Sandhoff disease cats. |
| Taysha Gene Therapies | It is a clinical-stage biotech company focused on advancing AAV-based gene therapies for severe diseases, including Sandhoff disease. |
| Passage Bio, Inc. | Passage Bio delivers genetic medicines for patients with neurodegenerative diseases. The Imaging-1 clinical trial tested AAVhu68 gene therapy PBGM01 for Sandhoff disease. |
Browse More Insights of Towards Healthcare:
The global predictive disease analytics market
The global inhaled therapy in respiratory disease market
The U.S. point-of-care infectious disease testing market
The global point-of-care infectious disease testing market
The global infectious diseases market
The global infectious disease diagnostics market
The global veterinary infectious disease diagnostics market
The global chronic disease treatment market
The global autoimmune disease diagnostics market
The global pelvic inflammatory disease treatment market
Recent Developments in the Sandhoff Disease Treatment Market
- In September 2025, Medipal Holdings Corporation announced a collaboration with JCR Pharmaceuticals Co. to co-develop and commercialize JR-479, an investigational therapy for GM2 gangliosidosis. JR-479 was developed using JCR's proprietary J-Brain Cargo platform. In August 2025, researchers from UMass Chan Medical School reported positive results of Phase I/II clinical trials of a dual vector gene therapy for GM2 gangliosidosis. The study found that gene therapy could induce the production of the appropriate enzyme, and the enzyme was functional.
Sandhoff Disease Treatment Market Companies
- Orchard Therapeutics REGENXBIO Inc. uniQure N.V. Sanofi S.A. Johnson & Johnson (Janssen R&D) Takeda Pharmaceutical Company Novartis AG Amicus Therapeutics Biomarin Pharmaceutical Inc. Pfizer Inc. (gene therapy platforms) Genzyme (Sanofi division) Bluebird Bio Cure Rare Disease (CRD) M6P Therapeutics IntraBio Inc.
The Sandhoff Disease Treatment Market Segmentation
By Therapy Type
- Supportive & Symptomatic Treatment
- Anticonvulsants Physical & occupational therapy Respiratory and nutritional support
- AAV-based or lentiviral vector therapies in early-stage trials
- Miglustat and analogs under investigation
- Experimental, not yet commercialized
By Disease Form
- Infantile Sandhoff Disease Juvenile Sandhoff Disease Adult Sandhoff Disease
By Drug Type
- Anticonvulsants & Muscle Relaxants Miglustat (investigational for off-label use) Experimental Gene Therapies
- HEXB gene vector programs in preclinical/Phase I stages
By Route of Administration
- Oral Intrathecal/Intravenous Inhalation & Nutritional Routes (supportive only)
By End-User
- Hospitals & Specialized Clinics Academic Medical Centers Homecare (limited to palliative management in advanced stages) Research Institutions
By Region
- North America
- U.S. Canada
- China Japan India South Korea Thailand
- Germany UK France Italy Spain Sweden Denmark Norway
- Brazil Mexico Argentina
- South Africa UAE Saudi Arabia Kuwait
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard:About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research You can place an order or ask any questions, please feel free to contact us at ...Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web:Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
- Thinkmarkets Adds Synthetic Indices To Its Product Offering
- Ethereum Startup Agoralend Opens Fresh Fundraise After Oversubscribed $300,000 Round.
- KOR Closes Series B Funding To Accelerate Global Growth
- Wise Wolves Corporation Launches Unified Brand To Power The Next Era Of Cross-Border Finance
- Lombard And Story Partner To Revolutionize Creator Economy Via Bitcoin-Backed Infrastructure
- FBS AI Assistant Helps Traders Skip Market Noise And Focus On Strategy
More Story
Comments
No comment